EUCOPE

The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) is a pharmaceutical industry trade association founded in 2008 with the view to give voice to small and medium-sized companies active in the research, development, production and distribution of pharmaceuticals and biotechnologies.
Via the member associations (French FranceBiotech, German BioDeutschland, the German Pharmaceutical Industry Association (BPI), the Ethical Medicines Industry Group (EMIG) of the UK, the Swedish Associations SwedenBio and IML as well as Greek association PEF) EUCOPE represents more than 900 mid-sized innovative member companies, many of them SMEs. EUCOPE membership includes
* innovative family-owned businesses such as Ferring, B.Braun or Vianex
* companies focusing on rare disease treatments such as Achillion, Actelion, Aegerion, Akcea, Alexion, Alnylam, Amicus, Biogen, BioMarin, Bluebird Bio, Celgene, Celsion, CSL Behring, Cytokinetics, Grifols, Horizon, Incyte, Intercept, Kite Pharma, CTRS, Medac, Miltenyi Biotech, Nordic Nanovector, Onxeo, Orphan Europe, Ovid, Prothena, PTC, Santhera, Santen, Sarepta, Sobi, Takeda, Tesaro, Vertex, Vifor Pharma, Zealand Pharma and Zogenix.
EUCOPE, inter alia, represents its members with respect to international governmental organisations in particular towards the EU institutions (Council of the EU, EU Commission, European Parliament) and agencies (including the European Medicines Agency).
Structure
* President of the Association: Jan G. Smith, ABIGO Medial AB, Sweden.
* Vice-President: Leslie Galloway, EMIG
* Vice-President: Gilles Pluntz, Ferring Pharmaceuticals
* Treasurer: Konstantinos Panagoulias, Vianex
* Secretary General: Dr. Alexander Natz
Policy Objectives
EUCOPE is active in the above-mentioned areas:
* Fast patient access to innovative medicines through:
**Transparent reimbursement and pricing decisions
** Timely marketing authorisation procedures
**Effective promotion of R&D by tax incentives
**increased multi-stakeholder collaboration
*Enhanced research and development of rare disease solutions (Orphan drugs)
*Fostered pharmaceutical innovation by biopharmaceutical SMEs with:
**Strong pharmaceutical intellectual property and incentives
**Incentives for incremental research
**Reduced VAT rates for pharmaceuticals
*Legislative files:
**European Health Technlogy Assessment (HTA)
**European Commission proposal for an EU Regulation introducing a Supplementary Protection Certificate (SPC) Manufacturing Waiver
**Recast of the clinical trials legislation
**European Medical Devices Regulation (MDR) and in-vitro diagnostics Regulation (IVDR)
**Pharmacovigilance

Main Menu

See Also

Main Menu